echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Consistency evaluation of omeprazole enteric coated capsules of Roxin pharmaceutical industry through generic drugs

    Consistency evaluation of omeprazole enteric coated capsules of Roxin pharmaceutical industry through generic drugs

    • Last Update: 2019-12-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    After more than three years of project breakthrough, omeprazole enteric coated capsule (20 mg) under Luoxin pharmaceutical was officially approved, becoming the first digestive drug of the company to pass the consistency evaluation Omeprazole enteric coated capsule is the first generation proton pump inhibitor, which is used to treat reflux esophagitis, duodenal ulcer and Zhuo AI syndrome Compared with the traditional antacids, proton pump inhibitors, as the standard drug of antacids, target to inhibit the abnormal gastric acid secretion at the level of molecular biological mechanism, so as to provide more safe and effective options for individual treatment of patients Omeprazole is the first proton pump inhibitor for clinical use It used to be a global heavyweight product with mature market At present, there are many enteric coated capsules and enteric coated tablets in China Drug intelligence data - hospital sales data show that: variety analysis accounts for: Although the market scale is large, sales are stable However, the consistency evaluation of omeprazole enteric coated capsules belongs to the super difficult variety, and the high variation and process are difficult At present, only Yangzijiang and Luoxin have been approved According to the pharmaceutical intelligence data: at present, 51 companies have submitted the application for the consistency evaluation of omeprazole enteric coated capsules At the evaluation stage, companies such as Changzhou siyao Pharmaceutical Co., Ltd and Hainan Hailing Chemical Pharmaceutical Co., Ltd sprout this article, which is the integrated content of pharmaceutical intelligence network, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.